Clinical Trial Update: Efficacy and Safety of Ingavirin®, Syrup, 30 mg/5 ml, in Children With Influenza and Other Acute Respiratory Viral Infections [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating the efficacy and safety of Ingavirin syrup (30 mg/5 ml) in children with influenza and acute respiratory viral infections.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Common Cold
• Respiratory Infection

Drugs mentioned

• Ingavirin

Snippet

Sponsor: Valenta Pharm JSC | Conditions: Influenza, Human, Acute Respiratory Infection | Phase 3 | Status: COMPLETED